CRISPR Therapeutics AG (CRSP)
56.19
+0.52
(+0.93%)
USD |
NASDAQ |
May 17, 16:00
55.91
-0.28
(-0.50%)
After-Hours: 20:00
CRISPR Therapeutics Gross Profit (TTM): 134.98M for March 31, 2024
Gross Profit (TTM) Chart
Historical Gross Profit (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 134.98M |
December 31, 2023 | 239.75M |
September 30, 2023 | 52.93M |
June 30, 2023 | 37.59M |
March 31, 2023 | -21.54M |
Date | Value |
---|---|
December 31, 2022 | -109.81M |
September 30, 2022 | -122.47M |
June 30, 2022 | -105.84M |
March 31, 2022 | 801.18M |
December 31, 2021 | 811.90M |
Gross Profit Definition
Gross profit is the difference between sales and the cost of goods sold. Revenues (aka Sales) less Cost of Goods Sold (COGS) is a company's gross profit. For many companies, cost of goods sold is a substantial portion of expenses.
Gross Profit (TTM) Range, Past 5 Years
-122.47M
Minimum
Sep 2022
811.90M
Maximum
Dec 2021
171.87M
Average
45.26M
Median
Gross Profit (TTM) Benchmarks
Vertex Pharmaceuticals Inc | 8.847B |
Novartis AG | 36.35B |
Intellia Therapeutics Inc | -- |
Regeneron Pharmaceuticals Inc | 11.31B |
Viking Therapeutics Inc | -- |